About
I am a chemist with extensive experience in molecular biology and bioinformatics. Over the past five years, I have led cross-disciplinary initiatives to investigate tuberculosis, atopic dermatitis, COVID-19, primary biliary cholangitis, and various cancers, culminating in over 50 published papers. My goal is to push the boundaries of computational biology and improve patient outcomes through innovation and collaboration. My lab is currently focused on pioneering technology development for single-cell and spatial transcriptomics, empowering researchers to uncover deeper insights into host-pathogen interactions. By uniting experimental and computational approaches, I seek to advance our understanding of complex disease mechanisms and drive meaningful transformations in global health.
Research
Research groups
Research interests
- Single-cell transcriptomics
- Systems immunology
- Bioinformatics and data analysis
- Next-generation sequencing
- Method development for drug screening
Current research
His current research focuses on advancing single-cell transcriptomics, computational biology, and systems immunology to unravel the molecular mechanisms underlying infectious diseases and cancer. By integrating next-generation sequencing (NGS) data, mathematical modeling, and innovative bioinformatics pipelines, he aims to discover novel diagnostic and therapeutic targets. A key aspect of his work involves bridging the gap between experimental (wet lab) and computational (dry lab) research, fostering a collaborative environment that accelerates scientific breakthroughs. This includes developing cutting-edge methods for single-cell analysis and improving drug screening techniques in partnership with industry leaders such as GlaxoSmithKline. His studies encompass a diverse range of diseases—tuberculosis, atopic dermatitis, COVID-19, primary biliary cholangitis, and various cancers—and emphasize the importance of continuous adaptation and cross-disciplinary colaboration.